After decades of underinvestment, a handful of drugs targeting the world's most dangerous bacteria are entering final-stage testing—but the broken economics of antibiotic development threaten to strand them before they reach patients
March 16th, 2026: FDA clears BV100 Phase 3 trial for US patient enrollmentNew here? Follow stories to track developments over time. Create a free account to get updates when stories you care about change.
No genuinely new class of antibiotic has reached patients since 1987, and in the nearly four decades since, bacteria have steadily evolved resistance to existing drugs. Carbapenem-resistant Acinetobacter baumannii—a hospital-acquired pathogen that kills up to 60 percent of ventilated pneumonia patients—is at the top of the WHO's list of critical-priority threats. On March 16, 2026, Swiss biotech BioVersys received FDA clearance to enroll American patients in a Phase 3 pivotal trial of BV100, which reduced 28-day mortality by half in earlier testing.
BV100 and Roche's zosurabalpin are the major Phase 3 entrants among only a few drugs in late-stage development against the deadliest gram-negative bacteria. Both face a paradox: new antibiotics are deliberately used sparingly, preventing them from generating enough revenue to recoup development costs. Without pull-incentive legislation like the reintroduced PASTEUR Act or the UK's subscription model, these drugs could remain out of reach even if they work.
No questions yet — be the first to ask.
Acinetobacter baumannii
Close-up image showing various pills and a thermometer, emphasizing health and medicine.
Close-up of metallic pills and blister packs on a dark surface, showcasing healthcare themes.
Drug-resistant superbugs projected to kill 39 million by 2050
KARE 11
Pipeline of new drugs to fight superbugs is 'worryingly thin.
The Indian Ocean Night Post
Drug companies aren't making new antibiotics. Is there an ...
PBS NewsHour
Images from Openverse under Creative Commons licenses. Videos from YouTube.
Curated perspectives — historical figures and your fellow readers.
Fictional AI pastiche — not real quote.
"How dreadfully modern of us — to discover the cure for death only to find we cannot afford to sell it. The bacteria, at least, have mastered the one economic principle that eludes our legislators: they invest in themselves continuously, and never once go bankrupt doing so."
Exploring all sides of a story is often best achieved with Play.
Your progress in this debate will be lost.
Choose one persona for each side of the debate
Choose personas with different perspectives for a more dynamic debate.
Select debater for this side:
No debate personas available right now.
Select debater for this side:
No debate personas available right now.
Make your prediction before the referee scores
Pick the question both personas must answer in the final round
Debate Oracle! You called every round!
Sharp Instincts! You know your debaters!
The Coin Flip Strategist! Perfectly balanced!
The Contrarian! Bold predictions!
Inverse Genius! Try betting the opposite next time!
Swiss biotech developing antibiotics and anti-virulence drugs against resistant bacteria, built on two proprietary platforms: TRIC (Transcriptional Regulator Inhibitory Compounds) and Ansamycin Chemistry.
The WHO designated carbapenem-resistant Acinetobacter baumannii as its number-one critical-priority pathogen and has repeatedly warned that the antibiotic pipeline is insufficient to address rising resistance.
The FDA's QIDP designation program, created by the 2012 GAIN Act, grants priority review, Fast Track status, and five additional years of market exclusivity to qualifying antibiotics—a key regulatory tool for incentivizing development against resistant pathogens.
Roche's zosurabalpin is a first-in-class tethered macrocyclic peptide that blocks lipopolysaccharide transport in Acinetobacter baumannii—one of only two drugs alongside BV100 in Phase 3 trials targeting CRAB.
January 1987 March 2026
The FDA cleared BioVersys to begin enrolling United States patients in the RIV-TARGET Phase 3 pivotal trial of BV100 for hospital-acquired and ventilator-associated pneumonia caused by CRAB. Results are expected by end of 2027, with regulatory submissions planned for 2028.
BioVersys published BV100's single ascending dose and multiple ascending dose Phase 1 data in Antimicrobial Agents and Chemotherapy, showing dose-proportional pharmacokinetics and a favorable safety profile in healthy volunteers.
Lawmakers reintroduced the Pioneering Antimicrobial Subscriptions to End Upsurging Resistance Act, proposing up to $6 billion in federal subscription contracts for new antibiotics, with updated qualification criteria and expanded stewardship provisions.
BioVersys announced the initiation of RIV-TARGET, the global Phase 3 pivotal trial of BV100 for hospital-acquired and ventilator-associated bacterial pneumonia caused by CRAB.
Roche began a Phase 3 trial of zosurabalpin, a first-in-class tethered macrocyclic peptide that blocks lipopolysaccharide transport in Acinetobacter baumannii, targeting approximately 400 patients.
BioVersys listed on the SIX Swiss Exchange under the ticker BIOV, raising 76.7 million Swiss francs to fund the BV100 program through planned regulatory submissions in 2028.
BioVersys announced last-patient-last-visit in its Phase 2 trial of BV100 for ventilator-associated pneumonia caused by CRAB. Results showed 28-day mortality of 25 percent versus 60 percent with best available therapy.
A landmark Lancet study projected that antimicrobial resistance would directly cause over 39 million deaths between 2025 and 2050, with annual mortality rising roughly 70 percent compared to 2022 levels.
The FDA approved Xacduro (sulbactam-durlobactam) for hospital-acquired and ventilator-associated pneumonia caused by Acinetobacter baumannii, providing the first targeted treatment. However, it is ineffective against strains producing metallo-beta-lactamases.
The National Health Service began piloting a subscription payment model for antimicrobials, paying fixed annual fees of 5 to 20 million pounds per drug regardless of volume used—decoupling revenue from sales for the first time.
The United States Centers for Disease Control and Prevention classified carbapenem-resistant Acinetobacter as an urgent public health threat in its 2019 Antibiotic Resistance Threats Report, the agency's highest threat level.
The FDA designated BV100 as a Qualified Infectious Disease Product, making it eligible for priority review, Fast Track status, and five additional years of market exclusivity upon approval.
Achaogen, maker of the antibiotic plazomicin, filed for bankruptcy after generating only $800,000 in sales despite spending $300 million on development. The failure became a defining example of the broken economics of antibiotic development.
The World Health Organization released its first-ever list of antibiotic-resistant bacteria posing the greatest threat to human health, placing carbapenem-resistant Acinetobacter baumannii at the top of the 'critical' category.
The last genuinely new class of antibiotics was introduced to clinical use. Every antibiotic approved since has been a derivative of existing classes, marking the start of a discovery void that persists nearly four decades later.
3 moments from history that rhyme with this story — and how they unfolded.
Achaogen spent roughly $300 million developing plazomicin (Zemdri), an aminoglycoside antibiotic for drug-resistant urinary tract infections, and secured FDA approval in June 2018. Within a year, the drug had generated only $800,000 in revenue. The company's stock fell 95 percent, and Achaogen filed for bankruptcy in April 2019, selling its assets for $16 million.
Plazomicin was acquired by a smaller firm at a fraction of its development cost. Multiple other antibiotic developers, including Melinta Therapeutics, filed bankruptcy in the same period.
The Achaogen collapse became the defining cautionary tale for antibiotic economics, directly motivating legislative proposals like the PASTEUR Act and demonstrating that FDA approval alone cannot sustain antibiotic companies.
BioVersys faces the same structural challenge: BV100 targets a rare pathogen and would be used sparingly even if approved, making traditional sales-based revenue inadequate. The difference is that pull-incentive mechanisms like the United Kingdom subscription model now exist and the PASTEUR Act is further along in Congress—but neither has yet proven sufficient at scale.
The FDA approved Xacduro (sulbactam-durlobactam), developed originally by Entasis Therapeutics and later acquired by Pfizer, as the first antibiotic specifically indicated for hospital-acquired and ventilator-associated pneumonia caused by Acinetobacter baumannii. Clinical trials showed non-inferiority to colistin—the toxic last-resort treatment—with higher clinical cure rates and significantly less kidney damage.
Hospitals gained a less toxic alternative to colistin for susceptible CRAB strains. However, the drug is ineffective against strains that produce metallo-beta-lactamase enzymes, limiting its coverage.
The approval demonstrated that targeted CRAB therapies could clear FDA scrutiny but also highlighted coverage gaps that the next generation of drugs—BV100, zosurabalpin—would need to address.
Xacduro's limitations—particularly its inability to treat metallo-beta-lactamase-producing CRAB—create the medical rationale for BV100, which uses an entirely different mechanism (active uptake of rifabutin) and is not affected by the same resistance pathways.
The United Kingdom's National Health Service launched the world's first subscription payment model for antimicrobials, paying fixed annual fees of 5 to 20 million pounds per antibiotic regardless of how many doses were used. The pilot, evaluated by the National Institute for Health and Care Excellence, was deemed successful. In 2024, the government committed 100 million pounds per year to scale the program across England, Scotland, Wales, and Northern Ireland, with full procurement contracts beginning April 2026.
Two antibiotics—ceftazidime-avibactam and cefiderocol—were enrolled in the pilot, providing a revenue floor that removed volume-based risk for their manufacturers.
The model established proof of concept that governments can decouple antibiotic revenue from prescription volume, influencing the design of the PASTEUR Act in the United States and prompting G7 discussions on coordinated international pull incentives.
The subscription model directly addresses the commercial failure pattern that threatens BV100 and every other antibiotic in development. Its expansion to full scale in April 2026—the same month BV100 begins US enrollment—could make the United Kingdom an early commercial market if BV100 wins approval.